Retatrutide Tracker: What Your Dose Log Must Record
What a retatrutide tracker must record (mg, syringe units, mL, vial strength, and the step), why retatrutide has no approved dose, what the published trials used, and how Vital keeps the math in each log.
Last reviewed
The Vital angle
Vital lists retatrutide in its peptide library with its investigational status. When you add a vial, you enter the mg in the vial and the water added, and Vital shows the concentration, the U-100 units and mL for the amount your prescriber gave you, and the doses per vial, with a warning when a draw is more than a 1 mL syringe holds. Each log keeps the unit, the vial mass and water, the site, symptoms with severity, lot number, and expiration date.
What a retatrutide tracker must do
A retatrutide tracker must record four numbers for every injection: the amount in mg, the draw in syringe units, the draw in mL, and the vial strength in mg/mL. It must also record the step (the amount used in that phase of the plan), the date and time, the site, and any side effects. Without the vial strength, a unit count means nothing, because a syringe unit is a volume, not an amount of drug.
Retatrutide is an investigational drug. It is not FDA-approved for any use, so no approved human dose or schedule exists. This page does not give one. It explains what to log, the facts from published trials, and how to keep the numbers consistent. Ask the prescriber or the trial team who set your plan about every dose.
Retatrutide regulatory status
Retatrutide (LY3437943) is an Eli Lilly compound that acts on the GIP, GLP-1, and glucagon receptors. As of November 20, 2026:
- ClinicalTrials.gov lists TRIUMPH-1, a Phase 3 trial of once-weekly retatrutide in adults with obesity or overweight, as completed. The sponsor is Eli Lilly and Company.
- The FDA says retatrutide is not a component of any FDA-approved drug and cannot be used in compounding under federal law.
- The FDA has sent warnings to companies that sold retatrutide labeled "for research purposes" or "not for human consumption" for people to use. It urges consumers not to buy these products, because their quality is unknown.
If you are in a trial, the trial team gives the dose, the injection device, and the instructions. Log what they give you.
What published trials used
These are facts about one trial, not a plan for anyone. In a Phase 2 trial published in the New England Journal of Medicine in 2023, 338 adults with obesity or overweight received retatrutide or placebo once weekly by injection for 48 weeks. The study groups were:
| Trial group | Starting amount | Target amount |
|---|---|---|
| 1 mg | 1 mg | 1 mg |
| 4 mg (two groups) | 2 mg or 4 mg | 4 mg |
| 8 mg (two groups) | 2 mg or 4 mg | 8 mg |
| 12 mg | 2 mg | 12 mg |
At 48 weeks, the mean weight change was -8.7% in the 1 mg group, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group, and -24.2% in the 12 mg group, compared with -2.1% on placebo. The most common side effects were gastrointestinal. They were dose-related and mostly mild to moderate, and a lower starting amount (2 mg vs 4 mg) partly reduced them. Heart rate rose with dose, peaked at 24 weeks, and then declined.
Two things follow for a log. First, the trial moved through steps, so a log must record the step and the date of each change. Second, side effects and heart rate changed with dose, so a log must connect each symptom to the step it happened on. For more, see retatrutide dosage chart.
The fields of a retatrutide dose log
| Field | Example entry | Why it matters |
|---|---|---|
| Date and time | Monday, 8:00 | Shows the real interval between doses |
| Amount | mg as your prescriber wrote it | The amount of drug, the number that counts |
| Vial strength | mg in the vial and mL of water added, or mg/mL on the label | Turns an amount into a volume |
| Draw | Units on the syringe and mL | What you actually measure |
| Syringe type | U-100, and its size | U-40 and U-100 marks differ by 2.5 times |
| Step | The phase of your plan | Connects side effects to dose changes |
| Site | Left abdomen, right thigh | Rotation |
| Symptoms | Nausea, severity 2 of 5 | Pattern over time |
| Batch | Lot number and expiration date | Traceability if there is a problem |
| Weight | Weekly reading | Progress over time |
The free weight loss calculator shows the percent of body weight lost. See also peptide injection log template.
Retatrutide units math with hypothetical numbers
These are hypothetical round numbers that show the math. They are not doses.
- Find the strength. Math example: a vial with 10 mg of powder mixed with 2 mL of water holds 10 ÷ 2 = 5 mg/mL.
- Find the volume. Math example: for a hypothetical 1 mg amount, 1 ÷ 5 = 0.2 mL.
- Convert to units. On a U-100 syringe, 1 unit is 0.01 mL, so 0.2 mL is 20 units.
- Count the doses in the vial. Math example: 10 mg ÷ 1 mg = 10 doses, before any loss in the vial.
Change one number and the units change. With the same vial mixed with 1 mL of water, the strength is 10 mg/mL, and the same 1 mg is 10 units. This is why units copied from someone else's vial are unsafe. The FDA reported overdoses with compounded semaglutide vials from this same unit confusion, including patients who drew 50 units instead of 5. Confirm every draw with your prescriber or pharmacist.
Use the free peptide calculator to check the math, and read retatrutide dose in units and mg, U-40 vs U-100 syringes, and how to read an insulin syringe for peptides.
How Vital keeps the math in each retatrutide log
Vital includes retatrutide in its peptide library, which shows it as investigational and not FDA approved. When you add a vial, you enter the mg in the vial and the water added. Vital shows the concentration in mg/mL and, for the amount your prescriber gave you, the draw in U-100 units and mL and the doses per vial. If the draw is more than a 1 mL syringe holds, the app warns you. You can also scan the vial label to start the entry.
Each log keeps the unit you used (mg, mcg, units, or mL), the vial mass and water, the site on a body map, the time, symptoms with a severity, notes, and the lot number and expiration date. A reminder can repeat on a set weekday or every few days. A "still in your system" card shows a half-life estimate after each dose. You can export a PDF dose history to bring to your prescriber or trial team. Vital does not suggest a dose or a step. For other apps, see best peptide tracker app, and if you also take a GLP-1 such as Zepbound, see GLP-1 and peptide tracker.
Retatrutide side effects log and warning signs
Log each symptom with the date, the severity, and the step you were on. In the Phase 2 trial, the most common side effects were gastrointestinal, such as nausea, and heart rate rose with dose. A dated log helps your care team see whether a symptom follows a step change.
Get care right away for any of these:
- Severe stomach pain that does not go away, which can spread to the back, with or without vomiting.
- Vomiting or diarrhea that stops you from keeping fluids down, or signs of dehydration such as dizziness or very little urine.
- Pain in the upper right belly, fever, or yellow skin or eyes.
- Swelling of the face, lips, or throat, or trouble breathing.
- A fast heartbeat at rest that does not slow down, or chest pain.
If you are in a trial, call the trial team about any new symptom. A tracker records what happened. It does not replace a call to your care team.
Zepbound® is a trademark of Eli Lilly and Company. Vital is independent and not affiliated with these companies.
Things to watch
Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.
No approved retatrutide dose
Retatrutide is investigational. The FDA says it is not a component of any approved drug and cannot be used in compounding under federal law.
Products labeled for research use
The FDA warned companies selling retatrutide labeled "for research purposes" or "not for human consumption" for people to use, and it urges consumers not to buy them.
Units copied from another vial
A syringe unit is a volume. The same units hold a different amount of drug when the vial mass or the water changes, so log the mg/mL with every draw.
mg, mL, and unit mix-ups
The FDA reported overdoses with compounded semaglutide vials from this confusion, including patients who drew 50 units instead of 5.
U-40 syringes with U-100 math
The marks on a U-40 syringe hold 2.5 times the volume of the same marks on a U-100 syringe. Record the syringe type in the log.
Side effects without the step
In the Phase 2 trial, gastrointestinal side effects and heart rate changes were dose-related. Log each symptom with the step you were on.
Frequently asked questions
Record the date and time, the amount in mg, the vial strength in mg/mL, the draw in units and mL, the syringe type, the step, the site, symptoms with severity, the lot and expiration date, and your weight.
Any tracker that accepts a custom peptide can log it. Vital lists retatrutide in its library. Retatrutide is investigational and has no approved dose, so a tracker should store the numbers your prescriber or trial team gave you and not suggest a dose.
There is no fixed number. Units depend on the vial strength. Math example with hypothetical numbers: at 5 mg/mL, 1 mg is 0.2 mL, or 20 units on a U-100 syringe. Confirm every draw with your prescriber or pharmacist.
In the published Phase 2 trial, groups received 1, 4, 8, or 12 mg once weekly for 48 weeks, some starting at 2 or 4 mg. These are trial facts, not guidance. No approved dose exists.
Log each symptom with a date, a severity, and the step you were on. In the Phase 2 trial, gastrointestinal effects were most common and heart rate rose with dose. Get care right away for severe stomach pain or vomiting that stops you from keeping fluids down.
Yes. In Vital, a reminder can repeat on a set weekday or every few days, as a notification or an alarm. Keep the day and time your prescriber or trial team set.
Sources
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) · ClinicalTrials.gov, U.S. National Library of Medicine
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial · The New England Journal of Medicine, via PubMed
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products · U.S. Food and Drug Administration
- Vital - Track Peptide & GLP-1 · App Store
This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.
Track every shot, every change
Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.
More from the Library
GLP-1 App Not Syncing With Apple Health or Health Connect
Why weight and other data do not move between a GLP-1 tracker and Apple Health or Health Connect, how read and write permissions work, and how to fix missing or duplicate weights.
Best GLP-1 Tracker App: Shotsy, MeAgain, Glapp, and Vital Compared
A fair roundup of GLP-1 tracker apps for Ozempic, Wegovy, Mounjaro, Zepbound, and compounded vials, with the selection criteria, the listing facts, and the date each one was checked. Vital publishes this page.
Best Peptide Tracker App: How Peptide Logs Compare on Blends, Units, and Site Rotation
A fair comparison of peptide tracker apps on blend math, syringe units, label scan, site rotation, reminders, and price, with the criteria and the date each listing was checked. Vital publishes this page.
How to Export Data From Shotsy and Keep Your Shot History
The ways to get your dose history out of Shotsy or any GLP-1 tracker: the app's own export, screenshots, Apple Health, a support request, and a clean manual record.